Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491

Condition:   Dilated Cardiomyopathy
Intervention:   Drug: MYK-491 or placebo
Sponsor:   MyoKardia, Inc.
Recruiting - verified February 2017

Metabolomics Study of Cardiomyopathy

Conditions:   Dilated Cardiomyopathy;   Hypertrophic Cardiomyopathy;   Arrhythmogenic Right Ventricular Cardiomyopathy;   Left Ventricular Non-compaction;   Restrictive Cardiomyopathy
Intervention:  
Sponsor:   Beijing Institute of Heart, Lung and Blood Vessel Diseases
Recruiting - verified February 2017

Effect of Dry-weight Probing Guided by Lung-Ultrasound on Ambulatory Aortic Blood Pressure and Arterial Stiffness in Hemodialysis Patients (LUST Sub-Study)

Conditions:   Chronic Kidney Disease;   Hemodialysis;   Hypertension
Interventions:   Procedure: Extra-vascular lung water measurements by ultrasound;   Other: Standard protocol of fluid management in hemodialysis
Sponsors:   Carmine Zoccali;   Aristotle University of Thessaloniki, Thessaloniki, Greece;   CNR-IBIM Clinical Epidemiology of Renal Diseases and Hypertension Unit, Reggio, Italy;   University Clinical Centre of Maribor, Slovenia
Recruiting - verified February 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified February 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified February 2017

Efficacy of Dotarem® (Gd-DOTA) Versus Magnevist® (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

Conditions:   Coronary Artery Disease;   Cardiomyopathy
Interventions:   Drug: Dotarem® (Gd-DOTA);   Drug: Magnevist® (Gd-DTPA)
Sponsors:   Dipan Shah;   Guerbet
Enrolling by invitation - verified February 2017

UTSW HP [13-C] Pyruvate Injection in HCM

Condition:   Cardiomyopathy, Hypertrophic
Intervention:   Drug: Hyperpolarized 13C-Pyruvate
Sponsor:   University of Texas Southwestern Medical Center
Not yet recruiting - verified February 2017

Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis.

Condition:   Aortic Valve Stenosis
Interventions:   Device: Symetis ACURATE neo/TF transfemoral TAVI system;   Device: Edwards Sapien 3 Transcatheter Heart Valve
Sponsors:   University Hospital Inselspital, Berne;   Kerckhoff Heart Center
Recruiting - verified February 2017

Mobile Health Behavioral Intervention in Patients With Heart Failure and Diabetes Mellitus

Conditions:   Diabetes Mellitus;   Heart Failure
Intervention:   Behavioral: mHealth
Sponsors:   Duke University;   Duke Clinical Research Institute;   American Heart Association
Not yet recruiting - verified February 2017

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Conditions:   Cardiomyopathy, Hypertrophic;   Cardiomyopathy, Hypertrophic, Familial
Intervention:   Drug: Perhexiline
Sponsor:   Heart Metabolics Limited
Recruiting - verified February 2017

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention:   Drug: Tafamidis meglumine
Sponsor:   Pfizer
Recruiting - verified February 2017

Advancing Symptom Alleviation With Palliative Treatment

Conditions:   Heart Failure;   Pulmonary Disease, Chronic Obstructive;   Emphysema
Intervention:   Behavioral: ADAPT Intervention
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Conditions:   Mild Tricuspid Regurgitation;   Moderate Tricuspid Regurgitation;   Tricuspid Regurgitation
Interventions:   Procedure: TV Annuloplasty;   Procedure: MVS Alone
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   German Society for Thoracic and Cardiovascular Surgery
Recruiting - verified February 2017

Molecular Imaging of Primary Amyloid Cardiomyopathy

Conditions:   Amyloidosis, Primary;   Cardiomyopathy
Interventions:   Radiation: F-18 florbetapir/C-11 acetate PET;   Device: MRI
Sponsors:   Brigham and Women's Hospital;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   American Heart Association
Recruiting - verified February 2017

(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)

Condition:   MITRAL REGURGITATION
Intervention:   Device: MITRACLIP
Sponsors:   Hospital Clinic of Barcelona;   Abbott
Recruiting - verified February 2017

Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Conditions:   Sarcoma, Soft Tissue;   Soft Tissue Sarcoma;   Undifferentiated Pleomorphic Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Synovial Sarcoma;   Myxofibrosarcoma;   Angiosarcoma;   Fibrosarcoma;   Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma
Interventions:   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: Olaratumab
Sponsor:   Washington University School of Medicine
Recruiting - verified February 2017

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Conditions:   Heart Failure;   Cardiomyopathy;   Ventricular Dysfunction
Interventions:   Biological: MPC Intramyocardial Injection;   Drug: Control Solution
Sponsors:   Annetine Gelijns;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2017

A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Condition:   LMNA-Related Dilated Cardiomyopathy
Intervention:   Drug: ARRY-371797, p38 inhibitor, oral
Sponsor:   Array BioPharma
Recruiting - verified February 2017

Interventions to Improve Daily Activity in Heart Failure

Condition:   Heart Failure
Interventions:   Behavioral: Activity Feedback and Encouragement;   Other: Health Coaching/Home Exercise
Sponsors:   Grand Valley State University;   Spectrum Health Hospitals
Completed - verified February 2017

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)

Condition:   Acute Heart Failure
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2017

Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure

Conditions:   Congestive Heart Failure;   Ischemic Cardiomyopathy
Intervention:   Drug: Micronutrients
Sponsor:   Phoenix VA Health Care System
Completed - verified September 2016